Pipeline


Pipeline Development

Novel Diagnostics & Innovative Therapeutics

Zomedica’s diagnostic pipeline aims to help veterinarians and their teams get better answers, faster via breakthrough technologies and by improving existing tests to accelerate speed to results while increasing sensitivity, specificity, performance and overall affordability.

Zomedica’s therapeutic pipeline is based on human approved drug formulations or compounded formulations that veterinarians already use to treat their patients. Zomedica’s therapeutic candidates are being formulated for animal physiology, tested for safety and efficacy, and submitted to the FDA Center for Veterinary Medicine (FDA-CVM) for approval.

Diagnostic Pipeline


Assay Development
Verification
Validation
Market Launch
  • ZM-024 // Point-of-Care Biosensor PlatformThyroid & Adrenal Disorder Immunoassays

    Zomedica has partnered with Qorvo Biotechnologies, LLC to collaborate on the development of a collection of rapid veterinary diagnostic assays with the goal to deliver reference-lab performance at the point of care. ZM-024 is expected to be comprised of a table-top instrument that uses disposable assay cartridges to test a range of samples including whole blood, serum, plasma, and urine. Joint development work initially targets five assay candidates to detect certain thyroid and adrenal disorders in dogs and cats, which currently require reference lab immunoassay testing for reliable diagnostic results. ZM-024 is an investigational device, is not currently available for sale, and is limited to investigational use only.

  • ZM-020 // Point-of-Care Pathogen Detection PlatformUrine & Fecal Testing

    Zomedica has partnered with Seraph Biosciences, Inc. to develop their in-clinic diagnostic analyzer for use in the detection of pathogens in companion animals. The ZM-020 diagnostic platform has the potential to screen for a wide range of pathogens in companion animal feces, urine, respiratory, and dermatological samples in minutes without the need for extensive sample prep or the use of reagents. The first tests Zomedica expects for release with the ZM-020 diagnostic platform will focus on the rapid detection of fecal parasites, potential UTI-associated urine bacteria and crystals, and leptospirosis using urine samples.

  • ZM-017 // Canine Cancer Liquid Biopsy PlatformHemangiosarcoma & Osteosarcoma

    Zomedica has partnered with Celsee, Inc. to develop their circulating tumor cell (CTC) “liquid biopsy” platform for use by veterinarians as a canine cancer diagnostic. ZM-017 aims to enable veterinarians to detect canine cancers in a manner that is faster, more affordable and less invasive compared to existing methods, which can be expensive and cost prohibitive for pet owners. The first assay Zomedica expects for release with ZM-017 targets hard-to-diagnose canine cancers, such as hemangiosarcoma and osteosarcoma.

    Get the White Paper
  • Assay Development
    • ZM-024 // Point-of-Care Biosensor PlatformThyroid & Adrenal Disorder Immunoassays

      Zomedica has partnered with Qorvo Biotechnologies, LLC to collaborate on the development of a collection of rapid veterinary diagnostic assays with the goal to deliver reference-lab performance at the point of care. ZM-024 is expected to be comprised of a table-top instrument that uses disposable assay cartridges to test a range of samples including whole blood, serum, plasma, and urine. Joint development work initially targets five assay candidates to detect certain thyroid and adrenal disorders in dogs and cats, which currently require reference lab immunoassay testing for reliable diagnostic results. ZM-024 is an investigational device, is not currently available for sale, and is limited to investigational use only.

    • ZM-020 // Point-of-Care Pathogen Detection PlatformUrine & Fecal Testing

      Zomedica has partnered with Seraph Biosciences, Inc. to develop their in-clinic diagnostic analyzer for use in the detection of pathogens in companion animals. The ZM-020 diagnostic platform has the potential to screen for a wide range of pathogens in companion animal feces, urine, respiratory, and dermatological samples in minutes without the need for extensive sample prep or the use of reagents. The first tests Zomedica expects for release with the ZM-020 diagnostic platform will focus on the rapid detection of fecal parasites, potential UTI-associated urine bacteria and crystals, and leptospirosis using urine samples.

  • Verification
  • Validation
    • ZM-017 // Canine Cancer Liquid Biopsy PlatformHemangiosarcoma & Osteosarcoma

      Zomedica has partnered with Celsee, Inc. to develop their circulating tumor cell (CTC) “liquid biopsy” platform for use by veterinarians as a canine cancer diagnostic. ZM-017 aims to enable veterinarians to detect canine cancers in a manner that is faster, more affordable and less invasive compared to existing methods, which can be expensive and cost prohibitive for pet owners. The first assay Zomedica expects for release with ZM-017 targets hard-to-diagnose canine cancers, such as hemangiosarcoma and osteosarcoma.

      Get the White Paper
  • Market Launch

Therapeutics Pipeline


Formulation
Pilot Studies
Pivotal Studies
Final FDA-CVM
Review
Market Launch
*FDA-CVM Phased Review
  • ZM-007 // Metronidazole Oral Suspension - Anti-DiarrhealFor small breeds and puppies

    ZM-007 and ZM-012 are complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs. ZM-007 is an oral suspension, currently only available via compounding pharmacies, for use with small dogs and puppies.

    Get the White Paper
  • ZM-012 // Metronidazole Tablet - Anti-DiarrhealApproved for use in humans

    ZM-007 and ZM-012 are complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs. ZM-012 is a tablet formulation currently only available as a human generic.

  • ZM-006 // Transdermal MethimazoleHyperthyroidism - Oral formulation approved for use in humans and cats

    ZM-006 is a transdermal gel formulation of methimazole targeting the chronic treatment of hyperthyroidism in cats. Intended for application to the cat’s ear, the transdermal gel is an alternative to conventional oral tablets already approved by the FDA Center for Veterinary Medicine for cats. Because of the associated difficulties with administering pills to cats, methimazole continues to be one of the most frequently compounded drugs in other dosage forms.

  • ZM-011 // Transdermal FluoxetineBehavioral Disorders, e.g. inappropriate urination, same API as Prozac®

    ZM-011 is a transdermal formulation of fluoxetine intended to treat behavioral disorders, such as inappropriate urination, in cats. Intended for application to the cat’s ear, the transdermal gel is most commonly known by its human pharmaceutical brand name Prozac® and is currently only available as a human-approved oral tablet or compounded drug.

  • Formulation
  • Pilot Studies
    • ZM-007 // Metronidazole Oral Suspension - Anti-DiarrhealFor small breeds and puppies

      ZM-007 and ZM-012 are complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs. ZM-007 is an oral suspension, currently only available via compounding pharmacies, for use with small dogs and puppies.

      Get the White Paper
    • ZM-012 // Metronidazole Tablet - Anti-DiarrhealApproved for use in humans

      ZM-007 and ZM-012 are complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs. ZM-012 is a tablet formulation currently only available as a human generic.

    • ZM-006 // Transdermal MethimazoleHyperthyroidism - Oral formulation approved for use in humans and cats

      ZM-006 is a transdermal gel formulation of methimazole targeting the chronic treatment of hyperthyroidism in cats. Intended for application to the cat’s ear, the transdermal gel is an alternative to conventional oral tablets already approved by the FDA Center for Veterinary Medicine for cats. Because of the associated difficulties with administering pills to cats, methimazole continues to be one of the most frequently compounded drugs in other dosage forms.

    • ZM-011 // Transdermal FluoxetineBehavioral Disorders, e.g. inappropriate urination, same API as Prozac®

      ZM-011 is a transdermal formulation of fluoxetine intended to treat behavioral disorders, such as inappropriate urination, in cats. Intended for application to the cat’s ear, the transdermal gel is most commonly known by its human pharmaceutical brand name Prozac® and is currently only available as a human-approved oral tablet or compounded drug.

  • Pivotal Studies FDA-CVM Phased Review
  • Final FDA-CVM Review FDA-CVM Phased Review
  • Market Launch

Voice of the Vet™

Be part of a veterinary community assembled to influence the development of solutions that fulfill real needs in veterinary practice.
Join Now

Investor Relations

Creating a diverse portfolio of diagnostics and therapeutics in the $10B companion animal market.

NYSE American:ZOM
TSX-V:ZOM
Learn More